Carcinoid Crisis: History, Dogmas, and Data

2021 ◽  
pp. 87-103
Author(s):  
Sarah M. Wonn ◽  
Rodney F. Pommier
Keyword(s):  
2019 ◽  
Vol 217 (5) ◽  
pp. 932-936 ◽  
Author(s):  
Kristen E. Limbach ◽  
Mary E. Condron ◽  
Ann E. Bingham ◽  
SuEllen J. Pommier ◽  
Rodney F. Pommier

Surgery ◽  
2021 ◽  
Author(s):  
Sarah M. Wonn ◽  
Anna N. Ratzlaff ◽  
SuEllen J. Pommier ◽  
Belinda H. McCully ◽  
Rodney F. Pommier

2018 ◽  
Author(s):  
Emily R Newton ◽  
Benjamin H Schmidt ◽  
Michael O Meyers

Although malignancies involving the small bowel are rare, one-third of these are located in the duodenum. The majority of duodenal tumors are adenocarcinoma but also may include gastrointestinal stromal tumors (GIST), carcinoid or neuroendocrine tumors, sarcomas, and lymphoma. These commonly present with nonspecific symptoms, but obstructive patterns predominate when symptoms are present. Preoperative diagnosis is made via endoscopy and/or cross-sectional imaging. This section focuses on treatment and surgical management for adenocarcinoma, carcinoid tumors, and GISTs of the duodenum. Surgical resection is the primary treatment of for all three of these, but all have significant nuances in surgical planning and decision-making as well as variability in the role of adjunctive treatment in their management. Functional carcinoid tumors can have hormone-driven symptoms and are associated with an increase in risk of carcinoid crisis, which may be prophylactically treated with intravenous octreotide. Resection of these tumors relies heavily on tumor relationship to the ampulla. Key anatomic distinctions and clinical tips to identify the ampulla to ensure an appropriate duodenal resection are discussed in this review. This review contains 12 figures, 5 tables, and 54 references. Key Words: carcinoid, duodenal carcinoma, duodenal adenocarcinoma, duodenal resection, duodenal tumors, neuroendocrine tumor, gastrointestinal stromal tumor, small bowel tumors


2016 ◽  
Vol 32 ◽  
pp. 189-193 ◽  
Author(s):  
Eugene A. Woltering ◽  
Anne E. Wright ◽  
Melissa A. Stevens ◽  
Yi-Zarn Wang ◽  
John P. Boudreaux ◽  
...  

Surgery ◽  
2019 ◽  
Vol 165 (1) ◽  
pp. 158-165 ◽  
Author(s):  
Mary E. Condron ◽  
Nora E. Jameson ◽  
Kristen E. Limbach ◽  
Ann E. Bingham ◽  
Valerie A. Sera ◽  
...  

2022 ◽  
pp. 201-212
Author(s):  
Sarah M. Wonn ◽  
Rodney F. Pommier

2018 ◽  
Vol 7 (12) ◽  
pp. 1245-1250 ◽  
Author(s):  
Myrtille Fouché ◽  
Yves Bouffard ◽  
Mary-Charlotte Le Goff ◽  
Johanne Prothet ◽  
François Malavieille ◽  
...  

Only few descriptions of intraoperative carcinoid syndrome (ioCS) have been reported. The primary objective of this study was to describe ioCS. A second aim was to identify risk factors of ioCS. We retrospectively analysed patients operated for small-bowel neuroendocrine tumour in our institution between 2007 and 2015, and receiving our preventive local regimen of octreotide continuous administration. ioCS was defined as highly probable in case of rapid (<5 min) arterial blood pressure changes ≥40%, not explained by surgical/anaesthetic management and regressive ≥20% after octreotide bolus injection. Probable cases were ioCS which did not meet all criteria of highly-probable ioCS. Suspected ioCS were detected on the anaesthesia record by an injection of octreotide due to a manifestation which did not meet the criteria for highly-probable or probable ioCS. A total of 81 patients (liver metastases: 59, prior carcinoid syndrome: 49, carcinoid heart disease: 7) were included; 139 ioCS occurred in 45 patients: 45 highly probable, 67 probable and 27 suspected. ioCs was hypertensive (91%) and/or hypotensive (29%). There was no factor, including the use of vasopressors, significantly associated with the occurrence of an ioCS. All surgeries were completed and one patient died from cardiac failure 4 days after surgery. After preoperative octreotide continuous infusion, ioCS were mainly hypertensive. No ioCS risk factors, including vasopressor use, were identified. No intraoperative carcinoid crisis occurred, suggesting the clinical relevance of a standardized octreotide prophylaxis protocol.


2020 ◽  
Vol 2 (13) ◽  
pp. 2068-2071
Author(s):  
Manoj V. Maddali ◽  
Catherine Chiu ◽  
Emily R. Cedarbaum ◽  
Vidhushei Yogeswaran ◽  
Mohamed Seedahmed ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document